- Home
- LYFT vs AXSM Comparison
LYFT vs AXSM Comparison
Compare LYFT & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYFT
- AXSM
- Stock Information
- Founded
- LYFT 2007
- AXSM 2012
- Country
- LYFT United States
- AXSM United States
- Employees
- LYFT N/A
- AXSM N/A
- Industry
- LYFT Business Services
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- LYFT Consumer Discretionary
- AXSM Health Care
- Exchange
- LYFT Nasdaq
- AXSM Nasdaq
- Market Cap
- LYFT 6.3B
- AXSM 5.1B
- IPO Year
- LYFT 2019
- AXSM 2015
- Fundamental
- Price
- LYFT $16.10
- AXSM $105.44
- Analyst Decision
- LYFT Buy
- AXSM Strong Buy
- Analyst Count
- LYFT 33
- AXSM 17
- Target Price
- LYFT $16.53
- AXSM $171.65
- AVG Volume (30 Days)
- LYFT 14.2M
- AXSM 649.3K
- Earning Date
- LYFT 08-06-2025
- AXSM 08-04-2025
- Dividend Yield
- LYFT N/A
- AXSM N/A
- EPS Growth
- LYFT N/A
- AXSM N/A
- EPS
- LYFT 0.14
- AXSM N/A
- Revenue
- LYFT $5,958,987,000.00
- AXSM $432,157,000.00
- Revenue This Year
- LYFT $14.15
- AXSM $62.84
- Revenue Next Year
- LYFT $12.81
- AXSM $60.02
- P/E Ratio
- LYFT $117.41
- AXSM N/A
- Revenue Growth
- LYFT 27.32
- AXSM 72.16
- 52 Week Low
- LYFT $8.93
- AXSM $72.21
- 52 Week High
- LYFT $19.07
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- LYFT 59.28
- AXSM 47.99
- Support Level
- LYFT $15.58
- AXSM $102.26
- Resistance Level
- LYFT $16.46
- AXSM $106.35
- Average True Range (ATR)
- LYFT 0.54
- AXSM 3.09
- MACD
- LYFT 0.05
- AXSM 0.15
- Stochastic Oscillator
- LYFT 86.47
- AXSM 66.44
About LYFT Lyft Inc.
Lyft is the second-largest ride-sharing service provider in the US and Canada, connecting riders and drivers over the Lyft app. Incorporated in 2013 and public since 2019, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft has entered the bike- and scooter-share market to bring multimodal transportation options to users.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.